FDA says Durect's pain relief drug Posidur needs additional safety studies
US drugmaker Durect Corp (Nasdaq: DRRX) says that the US Food and Drug Administration has issued a Complete Response Letter for Posidur (SABER-bupivacaine), the firm’s investigational drug for post-surgical analgesia. Durect's shares fell about 30%, closing at $1.95 on Wednesday on the news.
Based on its review, the FDA said it cannot approve the new drug application in its present form, stating the New Drug Application does not contain sufficient information to demonstrate that Posidur is safe when used in the manner described in the proposed label. The FDA has indicated that additional clinical safety studies need to be conducted.
Addressing the issues
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze